Drug Trial Radar · NCT05795595
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Mar 13, 2023
Primary completion
Sep 18, 2025
Study completion Sep 18, 2025
Sponsor
- Lead sponsor
- CRISPR Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
Conditions
- Clear Cell Renal Cell Carcinoma
- Cervical Carcinoma
- Esophageal Carcinoma
- Pancreatic Adenocarcinoma
- Malignant Pleural Mesothelioma
Interventions
CTX131Biological
CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (Dose Escalation): Incidence of adverse eventsTime frame: From CTX131 infusion up to 28 days post-infusion
- Phase 2 (Cohort Expansion): Objective response rate (ORR)Time frame: From CTX131 infusion up to 60 months post-infusion
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Research Site 3
Duarte, California
Research Site 7
Chicago, Illinois
Research Site 6
Boston, Massachusetts
Research Site 2
St Louis, Missouri
Research Site 4
Durham, North Carolina
Research Site 1
Nashville, Tennessee
Research Site 5
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.